Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trex001 in HLA-mismatched Living Donor Kidney Transplant Recipients
NCT03867617Phase 2Active, not recruiting
- Start
- Aug 2019
- Primary completion
- Jun 2024
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2 trial of regulatory T cells injection and tocilizumab in kidney transplantation (2 arms). Primary endpoints: Safety measured as GVHD, impaired graft function or patient death at 12 months and Chimerism at 1 month. Started Aug 2019; status: active, not recruiting.
02
Drugs
regulatory T cells injectiontocilizumab
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT03867617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867617.